. Author manuscript; available in PMC: 2012 Feb 15.

Published in final edited form as: Am J Cardiol. 2011 Feb 15;107(4):545–551. doi: 10.1016/j.amjcard.2010.10.013

Table 2.

Performance of Each Group during 12-week Acute Treatment Phase

Characteristics	Remission Group (N=208)		Non-Remission Group (N=194)		P value
	Sertraline	Placebo	Sertraline	Placebo
Treatment Assignment	26.4%	26.4%	22.4%	25.9%
Treatment Assignment	77.4±19.5	78.8±18.9	73.5±21.8	71.8±24.1	0.061
Days in 12-week intervention	(19–119)	(1–110)	(13–104)	(11–108)
Dosing	64.1±30.7	65.8±29.1	112.2±57.2	108.7±55.5	<.0001
	(50–150)	(50–200)	(50–200)	(50–200)
Last HDRS, mean (SD)	3.8±2.1	3.5±2.1	13.9±5.4	13.5±4.7	.0002
	(0–7)	(0–7)	(8–31)	(8–27)
Last BDI, mean (SD)	4.8±3.2	4.9±3.6	13.6±7.8	12.5±7.2	.0009
	(0–16)	(0–19)	(3–41)	(2–36)